Skip to main content

William A. Davis


[email protected]



Bill is a litigator and an integral member of the Health Care Enforcement Defense group. He devotes much of his practice to disputes concerning prescription drug price reporting, distribution, reimbursement, and rebates. He represents manufacturers in disputes with whistleblowers and state and federal officials around pharmaceutical pricing, and he regularly presents at national conferences concerning these issues. He also handles disputes involving pharmacy benefit managers, pharmacies, and payors regarding Medicare Part D, pricing issues, and other regulatory matters. Bill also has a commercial litigation practice and is the DC leader of Mintz’s Litigation Practice.

Bill leads the Litigation Practice in the firm’s DC office. He has broad experience representing corporations and individuals in a variety of complex commercial disputes, including litigation and arbitration involving health care, pharmaceuticals, medical devices, financial services, intellectual property, telecommunications, and securities, as well as disputes with the US government.

Before joining the firm, Bill practiced in the Washington, DC litigation department of a major New York-based law firm. Following his graduation from law school, he served as a law clerk to Chief Judge Alexander Harvey of the US District Court for the District of Maryland. During law school, he was a member of the Columbia Law Review.


  • Columbia University (JD)
  • University of Pittsburgh (BA, Economics)


  • Served as counsel for a global pharmaceutical company in a lawsuit alleging that a group of pharmaceutical manufacturers conspired to overstate the average wholesale price (“AWP”) for prescription drugs covered by the Medicare program. Plaintiffs advanced claims under §§ 1 and 2 of the Sherman Act and the RICO Act. Through our advocacy, we convinced plaintiffs to drop their claims against our client in their consolidated amended complaint, thereby concluding involvement in the matter without any liability.

Recognition & Awards

  • Phi Beta Kappa
  • Washington DC Super Lawyers: Business Litigation (2013)

Recent Insights



Deciphering the Final AMP Rule – Key Provisions Impacting Pharmacies, PBMs, and Manufacturers

February 10, 2016 | Advisory | By Theresa Carnegie, Ellyn Sternfield, Lauren Moldawer

In late January, the Centers for Medicare & Medicaid Services (“CMS”) released the much anticipated Covered Outpatient Drugs Final Rule with Comment (the “AMP Final Rule”).
Read more



18th Annual ACI Rx Drug Pricing Boot Camp

Incorporating Bona Fide Service Agreements in Pharmaceutical Pricing

237 S Broad St, Philadelphia, PA 19107


ACI's 16th National Rx Drug Pricing Master Course

American Conference Institute

Park Lane Hotel New York, NY